Squamous cell carcinoma: Difference between revisions
| Line 9: | Line 9: | ||
* Immunosuppression | * Immunosuppression | ||
* Chronic skin inflammation <ref>National Cancer Institute. Skin Cancer Treatment https://www.cancer.gov/types/skin/patient/skin-treatment-pdq</ref> | * Chronic skin inflammation <ref>National Cancer Institute. Skin Cancer Treatment https://www.cancer.gov/types/skin/patient/skin-treatment-pdq</ref> | ||
==Clinical Features== | |||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
Revision as of 17:03, 31 October 2019
Background
- Second most common skin cancer
- Higher rates of metastasis than basal cell carcinoma
Risk Factors
- UV radiation
- Chronic arsenic exposure
- Ionizing radiation
- Immunosuppression
- Chronic skin inflammation [1]
Clinical Features
Differential Diagnosis
Dermatologic malignancies
Evaluation
- Clinical examination by trained clinician (dermatology referral)
- Skin biopsy
Management
- Not typically managed within ED
Disposition
- Discharge with dermatology follow-up
See Also
External Links
References
- ↑ National Cancer Institute. Skin Cancer Treatment https://www.cancer.gov/types/skin/patient/skin-treatment-pdq